周一，Oppenheimer分析师上调了BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )的股票评级，从"持平"上调至"优于大市"，并设定目标价为$98.00。此次上调是基于BioMarin在2024年第四季度的强劲表现，公司总收入达到$747 million，超过市场预期的$712 ...

Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

周四，BMO Capital Markets维持BioMarin Pharmaceutical ...

Q4 2024 Management View CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS ...

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

VOXZOGO for achondroplasia experienced 56% year-over-year growth, driven by global expansion and increased penetration in younger pediatric patients. Management also revealed plans to expand ...

Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $711.9 million. Product revenues totaled $735.6 million, which rose 16% year over year on higher ...

UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...